Fibronostics is a discovery platform developing non-invasive, algorithm-based diagnostics to improve treatment outcomes, facilitate screening of specific diseases and help prognosis in various chronic conditions.
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity.
STALICLA is a clinical-stage biopharmaceutical company with a team of domain experts, drug developers, clinicians, data scientists and computational biologists working to create NDD precision medicine solutions.
Our venture companies receive the full backing of SPRIM. Working within the SPRIM family allows our investments to not only achieve funding, but leverage the global SPRIM organization to realize growth.